Comments
Natco Pharma's marketing partner Alvogen has received final approval to market oseltamivir phosphate powder used for the treatment of influenza in the US.
“Alvogen has received final approval and is the first to market generic equivalent to oseltamivir phosphate, 6 mg/ml powder for oral suspension in the United States,” Natco Pharma said in a regulatory filing today.
In December last year, Alvogen had launched the first generic equivalent to oseltamivir phosphate capsules in the United States.
Shares of Natco Pharma were trading at Rs 949.55 per scrip on the BSE, down 4.73 per cent from their previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.